The PREVENTABLE Study will help researchers learn if statins can help older adults live well for longer.
Edinburg, TX (October 12, 2020) — DHR Health Institute for Research and Development and DHR Health announced today that enrollment is now open for a new clinical trial called PREVENTABLE. The study will investigate whether taking atorvastatin, a drug commonly used to lower cholesterol also called Lipitor®, can help adults aged 75 and over maintain health by preventing dementia, disability, and heart disease.
The study, which aims to be one of the largest ever conducted in older adults, will include more than 20,000 participants and 100 sites across the U.S. The study will randomize participants without heart disease or dementia to receive either atorvastatin or placebo. Researchers will follow participants for up to five years and test their memory, thinking, physical abilities, and monitor them for events such as heart attacks or strokes.
It is a pragmatic study, designed to make research participation easy and efficient. Researchers will follow participants using electronic health records, Medicare data, and with study visits over the telephone. Study drug will be shipped directly to participants’ homes every three months.
“PREVENTABLE is a remarkable study for a number of reasons,” said Sohail Rao, MD, MA, DPhil, President and CEO, DHR Health Institute for Research and Development. “Few studies have focused exclusively on individuals aged 75 or older. While statins have been shown to reduce the risk of cardiovascular events for some patients, PREVENTABLE will help us to learn whether they are helpful for older adults without heart disease.”
About one in three people in the U.S. over the age of 75 without heart disease are taking statins. So in addition to learning whether statins can prolong health in older adults, the PREVENTABLE study will help clarify which older adults should not be taking statins. Watch this video to learn key aspects of PREVENTABLE and why this study is important to older adults.
“Patients often ask me what they can do to stay healthy and prevent dementia.” said Karen Alexander, MD, a geriatric cardiologist at Duke University Medical Center and principal investigator for PREVENTABLE. “This study will help to clarify the benefit of statins for this population. This is important to do before adding one more medication to the list of medicines older adults are often already taking. Results from this study will help us provide valuable answers to improve how we age.”
The study will randomize participants without heart disease or dementia to receive either atorvastatin or placebo. The placebo looks like the study drug, but has no medicine in it. Researchers will follow participants for up to five years and test their memory, thinking, physical abilities, and monitor them for future events such as heart attacks or strokes.
PREVENTABLE is funded by the National Institute of Aging and the National Heart, Lung, & Blood Institute of the National Institutes of Health under award number U19AG065188. To learn more about PREVENTABLE, visit www.preventabletrial.org. To find out who can take part in the study, or for more information, please contact 956-362- 2391 or email email@example.com.